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Introduction
Obesity in pregnancy has harmful effects on maternal health.[1,2]
Moreover, the mother’s increased adiposity has been suggested 
to influence the programming of metabolic pathways in the 
fetus, predisposing it to cardiovascular disease and diabetes[3,4] 
due to epigenetic mechanisms.[5]
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Abstract
Background: Obesity in pregnancy can contribute to epigenetic changes. Aim: To assess 
whether body mass index (BMI) in pregnancy is associated with changes in the methylation 
of the peroxisome proliferator‑activated receptor γ (PPAR) promoter region (−359 to − 260) 
in maternal and neonatal leukocytes. Subjects and Methods: In this matched, cohort 
study 41 pregnant women were allocated into two groups: (a) Normal weight (n = 21) 
and (b) overweight (n = 20). DNA was extracted from maternal and neonatal leukocytes 
(4000–10,000 cells) in MagNA Pure (Roche) using MagNA Pure LC DNA Isolation Kit 
1 (Roche, Germany). Treatment of DNA (2 µg) was performed with sodium bisulfite (EZ 
DNA Methylation‑Direct™ Kit; Zymo Research). Real‑time quantitative polymerase chain 
reaction (qPCR) was performed in a LightCycler 2.0 (Roche) using the SYBR® Advantage® 
qPCR Premix Kit (Clontech). The primers used for PPARγ coactivator (PPARG) M3 
were 5’‑aagacggtttggtcgatc‑3’ (forward), and5’‑cgaaaaaaaatccgaaatttaa‑3’ (reverse) 
and those for PPARG unmethylated were: 5’‑gggaagatggtttggttgatt‑3’ (forward) and 
5’‑ttccaaaaaaaaatccaaaatttaa‑3’ (reverse). Intergroup differences were calculated using the 
Mann–Whitney U‑test, and intragroup differences, with the Wilcoxon test (IBM SPSS 
Statistics for Windows, Version 19.0. Armonk, NY: IBM Corp.). Results: Significant 
differences were found in BMI, pregestational weight, and postdelivery weight between 
groups but not in the methylation status of the PPARγ promoter region (−359 to  − 260). 
Conclusion: The PPARγ promoter region (−359 to − 260) in peripheral leukocytes is unlikely 
to get an obesity‑induced methylation in pregnancy.
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A newly recognized primary cause of obesity epidemic 
is the developmental programming effects of normal or 
excessive weight newborns exposed to maternal obesity 
and high-fat diets.[6] During embryonic development, an 
appropriate DNA methylation state should be maintained 
during the rapid step cycles of cell proliferation.[7] It 
has been postulated that maternal obesity may impair 
DNA methylation of imprinted genes,[8] but the detailed 
mechanisms underlying these changes remain unknown. 
Other studies have shown that the expression of peroxisome 
proliferator-activated receptor α (PPAR) is regulated by 
DNA methylation in its promoters.[9,10] Following this 
line, PPARγ is a member of the hormonal nuclear receptor 
superfamily[11] with four known isoforms.[12] PPARγ1 and-γ2 
are expressed predominantly in adipocytes,[13] and the former 
is additionally expressed in breast, colon, vascular cells and 
in small amounts, in the heart and liver.[14] PPARγ3 and-γ4 
have been identified in macrophages, and PPARγ3 has been 
found in colon.[12]
PPARγ participates in the differentiation of preadipocytes 
into adipocytes,[15] meaning that a permanent activation 
of this gene could explain a higher incidence of obesity 
at lower age in children born to obese women. Persistent 
alteration in mRNA expression of PPARγ promoter region 
(−359 to −260) methylation has been associated with an 
increased risk of colon cancer,[16] hyperhomocysteinemia,[17] 
liver inflammation, and fibrosis in patients with hepatitis 
B,[18] etc. Our main objective was to assess whether 
clinical, anthropometric, and biochemical variables of the 
mother were associated with changes in the methylation 
of this PPARγ promoter region in maternal and neonatal 
leukocytes.
Subjects and Methods
Ethical clearance was granted by the Research Committee 
of the Maternal-Perinatal Hospital “Mónica Pretelini Sáenz” 
(HMPMPS) (code: 05-06-2009) and followed the General 
Health Research Law of Mexico, and the Declaration of 
Helsinki (Fortaleza, Brazil). All patients were asked to sign 
written informed consent.
Study site and design
This was a matched cohort study conducted from July 2009 to 
September 2012, at the tertiary health level HMPMPS, Health 
Institute of the State of Mexico, Toluca, Mexico.
Study population and ethical issue
Pregnant women were recruited in the first trimester of 
pregnancy and did not include cases with congenital heart 
and disabling or autoimmune diseases, this information was 
obtained from medical records in the first obstetrical visit. 
Those whose clinical follow-ups were lost or who, if in the 
postpartum required attention at the Obstetric Intensive Care 
Unit were eliminated from the study (n = 2).
Sample size
Accepting an alpha risk of 0.05 and a beta risk of 0.2 in a 
two-sided test, twenty subjects per group were necessary 
to find as statistically significant a proportion difference in 
the methylation status of the PPARγ promoter region (−359 
to −260), expected to be of 0% in pregnant women with normal 
weight (NW) and 40% in those with overweight (OW).
Data collection techniques and tools
One clinical visit per month was established. Body weight and 
height were measured during an overnight fasting state using 
an adult scale (Seca, Hamburg, Germany). Prepregnancy body 
mass index (BMI) was calculated as weight in kg divided by 
height in square meters based on the prenatal chart or on the 
self-reported weight of women with no prenatal chart.
Blood pressure was recorded at each visit using a standard 
sphygmomanometer (Riester Big Ben® Square; Jangingen, 
Germany). Preeclampsia was diagnosed and classified 
according to the American College of Obstetricians and 
Gynecologists guidelines.
Fasting blood samples (10 ml) were taken at the HMPMP 
Laboratory at an early-morning appointment after an overnight 
fast of 8 h. Serum samples were analyzed for glucose and lipid 
profile (Dimension RxL Max™; Dade Behring, USA). At the 
end of pregnancy, 1‒2 ml of a neonatal peripheral blood sample 
for leukocyte extraction was taken.
Dietetic treatment was calculated according to the height, 
weeks of gestation, and weight, considering an energy intake 
of 30 kcal/kg of ideal weight and a macronutrient distribution 
of 55‒65% carbohydrates, 10‒20% fat, and the remainder as 
proteins. On each nutritional appointment, the Healthy Eating 
Index for Pregnancy (HEI) was evaluated and all women 
were recommended to include methionine-rich foods (beans, 
eggs, fish, garlic, lentils, onion, and soy) and those containing 
folic acid and Vitamin B12 (beef liver, cereals, whole grains, 
yeast, etc.) in adequate quantities in their diet. The information 
was complemented with the Food Frequency Questionnaire, 
and adherence to the diet was considered adequate with 
80% compliance to the indicated calories, on at least four 
appointments.
Leukocytes were obtained according to the ACK lysing 
buffer (Lonza) protocol.[19] Briefly, a peripheral blood sample 
was placed in an EDTA tube and then centrifuged at 2500 rpm 
for 10 min. All samples were maintained at −80°C until further 
analysis.
DNA was extracted from maternal  and neonatal 
leukocytes (4000‒10,000 cells) in the Magna Pure LC 2.0 
Instrument (Roche, Germany) using MagNA Pure LC DNA 
Isolation Kit 1 (Roche, Germany).[20] After extraction, the 
DNA was quantified using a NanoPhotometer (Implen GmbH, 
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Germany), reporting concentration (in µg/ml) and purity (as 
260/280 absorbance).
Treatment of DNA (2 µg) was performed with sodium 
bisulfite (EZ DNA Methylation‑Direct™ Kit; Zymo Research). 
For the control group, we used purified human methylated 
and unmethylated (U3) DNA (Zymo Research) with specific 
oligonucleotides. Lymphocyte DNA from healthy nonpregnant 
donors was used as negative control and DNA methylated 
in vitro with the Sss I enzyme (New England BioLabs) was 
used as positive control for methylation.
The methylated (M3) and U3 primers employed were those 
proposed by Pancione et al.[16] These primers comprise the same 
region, that is, −359 to − 260, with respect to the transcription 
site, but differ in sequence with respect to cytosines of the CpG 
islands. The M3 primer set is specific to the case in which 
CpG cytosines are methylated, thus not modified, during the 
bisulfite treatment, whereas the U3 primer set is specific for 
the opposite case, that is, in which all cytosines are modified 
during bisulfite treatment.
Primer functionality was verified utilizing the following 
methods: First, by analyzing the primer sequences based 
on the in silico change of the gene sequence obtained from 
PubMed (NC_000003.11), and second, by obtaining theoretical 
products and running primer tests of specificity in the 
methBLAST sequence similarity search program.
In the polymerase chain reaction (PCR) analysis the 
primers employed for PPARγ coactivator (PPARG) 
M3 were: 5’-aagacggtttggtcgatc-3’ (forward) and 
5’-cgaaaaaaaatccgaaatttaa-3’ (reverse) and those for 
PPARG U3 were: 5’-gggaagatggtttggttgatt-3’ (forward) and 
5’-ttccaaaaaaaaatccaaaatttaa-3’ (reverse). In a life express 
thermal cycler (Bioer, China), the steps were as follows: (1) 
denaturation: 90°C for 15 s, (2) amplification (32 cycles): 95°C 
5 s, 53°C 20 s, 72°C 30 s, and 76°C 30 s. DNA integrity and 
methylation status were visualized in 2% agarose gels, stained 
with ethidium bromide, and visualized under an ultraviolet 
transilluminator (Gel Logic 212 Pro, Carestream, USA). 
Finally, PCR products were sequenced and read with Chromas 
software version 2.33 (Instituto de Neurobiología, National 
Autonomous University of Mexico, UNAM, Juriquilla, 
Querétaro, Mexico) to verify correct primer amplification.
Data analysis
Statistical analysis was performed using SPSS version 19 (IBM 
SPSS Statistics for Windows, Version 19.0. Armonk, NY: IBM 
Corp.). First, descriptive analyses were performed; then, we 
estimated the differences between the study groups using the 
Mann–Whitney U-test or the Student’s t-test depending on 
the Kolmogorov test to determine the distribution of the data. 
Finally, through the paired sample t-test or the Wilcoxon test 
we compared whether the same group presented differences 
across time. Difference was considered significant at P ≤ 0.05.
Results
Forty-one pregnant women were allocated into two groups: (a) 
NW pregnant women (n = 21) and their offsprings and (b) 
OW pregnant women (n = 20) and their offsprings. The 
anthropometric variables of the pregnant women are listed in 
Table 1. The weight of the newborns was 2999 (381) g and 
2958 (616) g for those of NW and OW women, respectively, 
and infant length was 49.55 (2.13) cm and 49.32 (3.06) cm for 
those of NW and OW women, respectively.
On analyzing all of the data, we found no statistical differences 
in age, pregnancy duration, or net weight gain, but significant 
differences were found in BMI, pregestational weight, and 
postdelivery weight between groups.
In blood pressure, no statistical differences could be established 
with the Friedman test, except for the third-trimester pregnancy 
for the OW group. We also performed a similar analysis among 
trimesters, comparing both groups and obtaining the same 
unique exception (data not shown). Only one confirmed case 
of preeclampsia occurred within the OW group. This patient 
exhibited outstanding cholesterol and triglyceride values.
Table 2 summarizes intragroup statistical results compared 
by trimester, demonstrating the following cases: (a) Variables 
with which evolution presented no statistical differences (this 
is the case of glucose in the NW group and of high-density 
lipoprotein cholesterol in both groups), (b) one variable with 
an increase from the first to the second trimester, followed 
by stagnation (glucose in the OW group), (c) variables that 
increased continuously (cholesterol in the NW group and 
triglycerides in both groups), (d) variables that showed 
differences in relation to the first trimester (cholesterol in the 
OW group, low-density lipoproteins cholesterol in both groups, 
and weight-gain in the OW group), and (e) one variable with 
an increase from the second to the third trimester (weight gain 
in the OW group). From these data, we can observe that the 
majority of the variables had a significant statistical difference 
when compared against the first trimester (eight cases with the 
second trimester and eight cases with the third trimester). As for 
the intergroup analysis (NW vs. OW), we found no statistical 






Age (years) 23.9 (5.4) 25.9 (6.9)
PGW (kg) 54.5 (6.7) 68.1 (10) <0.001
Height (cm) 158.5 (6.8) 154.7 (3.9)
BMI (kg/m2)* 21.6 (1.9) 28.5 (3.8) <0.001
PDW (kg) 62.4 (6.4) 70.7 (9.9) <0.001
BMI (kg/m2)† 24.8 (2.1) 29.5 (3) <0.001
Weight gain (kg) 11.1 (3.2) 9.0 (6.2)
*Prepregnancy, †Postdelivery. SD: Standard deviation; BMI: Body mass index, 
PGW: Pregestational weight, PDW: Postdelivery weight
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differences, except for weight gain during the first‑trimester 
visit, 2.3 (2.2) kg versus − 0.38 (3) kg, respectively (P < 0.01).
Taking into  account  the  pregnancy weight-gain 
recommendations of 11.5‒16 kg for NW and of 7‒11.5 kg 
for the OW case,[21] the percentage of pregnant women who 
maintained an ideal weight gain was 33.3% (7/21) in the NW 
and 40% (8/22) in the OW group. According to HEI, there was 
adequate adherence to nutritional counseling in 38.1% (8/21) 
of women in the NW group and in 25% (5/20) of women in 
the OW group.
All maternal and neonatal peripheral leukocyte samples 
were found to be U3 in both groups. These results were 
verified by both quantitative PCR amplification with the 
unmethylation‑specific primer and the absence of amplification 
in the presence of the methylation‑specific primer [Figure 1].
Discussion
The methylation status of g (PPARGC1A and PPARγ genes has 
shown to be important for the study of metabolic programming, 
and a role has been postulated of the BMI in this effect. In our 
study with pregnant women, the compared groups differed 
in weight-related variables, with essentially no statistical 
differences for all remaining variables. This is an appreciable 
characteristic because it limits any other difference aside 
from the effects of BMI. Other than BMI, both groups had 
differences in postpartum weight. When recalculating BMI 
after delivery, the initial NW group was found within the 
classification of OW, and the initial OW group fell into the 
obesity grade I range. The NW group was noted as having a 
higher net weight gain because recommendations are more 
extensive in these women.
Surprisingly, when comparing biochemical variables between 
groups among the trimesters, no statistical difference was 
found among these although it must be clarified that the cohort 
groups followed different trends and the intragroup difference 
for cholesterol and triglycerides from the first to the second 
and third trimester in each group could be associated to the 
BMI increase. In this behavior, pregnant women who adhered 
to the nutritional guidance afforded exhibited a slight decrease 
in weight gain, probably due to the influence of the dietetic 
orientation. In analyzing adherence to nutritional guidance, 
this action apparently contributed to the moderate weight 
gain, probably because of the influence of the diet orientation.
Regarding gestation weeks and the weight and length of the 
newborn at birth, no differences were found. While Grados 
Valderrama et al.[22] found a positive correlation between 
newborn weight and maternal BMI and weight gain, we found 
no correlation, probably because of the reduced study group size.
In pregnancy, it is normal to have hyperlipidemia.[23,24] 
Indeed, the increase in cholesterol is necessary because it is 
Table 2: Biochemical variables grouped by trimester*
Variable Group
NW trimester OW trimester
1 2 3 1 2 3
Cholesterol (mg/dL) 173 (36) 216 (46) 249 (63) 175 (21) 219 (47) 232 (49)
P <0.001x <0.001y <0.001z <0.001x 0.09y <0.001z
Glucose (mg/dL) 84 (12) 78 (8) 76 (7) 82 (5) 77 (6) 78 (7)
P 0.07x 0.25y 0.06z <0.01x 0.51y 0.05z
HDL-C (mg/dL)† 62 (28) 64 (16) 62 (14) 52 (8) 60 (16) 54 (12)
P 0.07x 0.44y 0.144z 0.05x 0.11y 0.37z
LDL-C (mg/dL) 101 (33) 130 (38) 145 (54) 102 (20) 131 (39) 146 (43)
P <0.001x <0.09y <0.001z <0.001x 0.07y <0.001z
Triglycerides (mg/dL) 136 (56) 201 (75) 247 (60) 147 (51) 215 (67) 255 (65)
P <0.001x <0.01y <0.001z <0.001x <0.01y <0.001z
Weight gain (kg) 2.3 (2.2) 3.8 (3.1) 4.7 (2.6) −0.38 (3) 3.6 (3.5) 5.7 (3.9)
P 0.11x 0.38y <0.01z <0.01x 0.09y <0.001z
*Results expressed in mean (SD), †Wilcoxon test was used when analyzing the HDL-C values of the first trimester, xFirst trimester versus second trimester, ySecond trimester versus third 
trimester, zFirst trimester versus third trimester. HDL-C: High-density lipoprotein cholesterol, LDL-C: Low-density lipoprotein cholesterol, NW: Normal weight, OW: Overweight
Figure 1: Agarose gel with the following explanation: M: Methylated; 
U3: Unmethylated; S: Sample; +C: positive control; −C: negative control
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the precursor of Vitamin D[25] and corticosteroid hormones, 
both critical for a healthy pregnancy.[26] In this study, we 
observed an increase of cholesterol in both groups that was 
higher in the third quarter of pregnancy. High cholesterol 
levels in pregnancy were believed to actually give rise to fetal 
programming for atherogenesis.[27]
Solomon et al.[28] found that pregnant women with high 
cholesterol levels and elevated insulin levels were more likely 
to develop pregnancy-induced hypertension or preeclampsia.
In our study, although cholesterol and triglycerides increased in 
both groups, the increase was more noticeable in triglycerides. 
As published previously, triglyceride levels increase up to three 
times as long as the pregnancy progresses through the third 
quarter.[5] Similar results were obtained in this study, suggesting 
changes in lipid metabolism, which may be accompanied by 
functional and morphological changes in adipocytes.
In our approach, we found no different methylation 
index in any case. In fact, all samples were found to be 
U3. Previous efforts have been performed to analyze the 
methylation changes in several genes, including PPARγ, 
with contrasting results.[29,30] Data from Jacoby et al.[31] 
suggest that inter-individual variability and co-regulation of 
DNA methylation differ among blood cell populations. It is 
noteworthy that each author might choose a different region 
of the same gene to be analyzed. The diet program during 
pregnancy should also be considered because strict diet 
supervision guaranteed adequate portions of methionine, folic 
acid, and Vitamin B12, all with a known role in preventing 
methylation disequilibrium.
The available information is overwhelming, in showing that 
the PPARγ2 promoter is particularly sensitive to nutritional 
changes.[32,33] Even more, animal models have shown that 
offspring of diet-induced obese dams have altered mRNA 
expression of PPARγ.[34,35] Thus, methylation status is one of 
the epigenetic changes that can explain maternal programming 
of metabolic syndrome-related phenotypes,[36] but further work 
is required to define the role of PPARγ.
It cannot be ruled out that the enzymatic activity in each tissue 
is of paramount importance because the profile of methylation 
observed in leukocytes might be different from fat tissue, which 
is directly involved in metabolic balance and obesity.
Finally, despite the great efforts invested in explaining some 
possible factors that predispose to obesity genetically and 
epigenetically, a single locus has not yet been identified as being 
entirely responsible for this pathology. Whether epigenetic 
reprogramming that operates during oocyte formation and in 
the initial stages of embryogenesis[37] is involved in the obesity 
transgenerational inheritance has not been clarified. The current 
trend, given the advances in molecular biology presented in 
the last few years, is to search for Genome-wide associations, 
which can provide a better understanding of the pathology of 
obesity and transgenerational health consequences.[38]
A limitation of this study is the evaluation of a sole promoter 
region, but the negative results in mothers and babies for a 
methylated status points out the relevance of evaluating other 
PPARγ promoter regions that could be useful in the maternal 
programming of metabolic diseases on the fetus. A significant 
edge of our work is the fact that while most of the studies related 
to the PPAR methylation have been performed in solid organ 
tissues,[39,40] the analysis in neonatal blood, as we did, is scarce.[30]
Conclusion
While further work is required to define in detail the epigenetic 
changes induced by obesity in pregnancy, our results show that 
the PPARγ promoter region (−359 to − 260) is unlikely to be 
easily methylated in peripheral leukocytes in this physiological 
weight gain condition.
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